Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice
Posted inGastroenterology Internal Medicine news

Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice

The SHARP randomized clinical trial finds that minor papillotomy does not significantly reduce the risk of recurrent acute pancreatitis in patients with pancreas divisum. These results challenge long-standing clinical practices and emphasize the need for sham-controlled evidence in interventional gastroenterology.
Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
Posted inInternal Medicine news Respiratory

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managing this debilitating and often refractory symptom.
Rethinking Rhythm Management: Catheter Ablation Outperforms Medical Therapy in Atrial Fibrillation Patients with High Comorbidity Burden
Posted inCardiology Internal Medicine news

Rethinking Rhythm Management: Catheter Ablation Outperforms Medical Therapy in Atrial Fibrillation Patients with High Comorbidity Burden

A post hoc analysis of the CABANA trial reveals that catheter ablation significantly reduces major cardiovascular events and improves quality of life in AF patients with high comorbidity burden (≥4 conditions), suggesting that multimorbidity should not be a barrier to invasive rhythm control strategies.
Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER
Posted inCardiology Internal Medicine news

Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER

A critical reanalysis of the DAPA-HF and DELIVER trials reveals that the survival proportional odds model provides greater statistical power and more robust treatment effect estimates than traditional Cox regression in heart failure populations characterized by high risk heterogeneity.
Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care
Posted inCardiology Internal Medicine news

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting the complexities of implementing precision medicine in clinical practice.
Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF
Posted inCardiology Internal Medicine news

Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF

The STEEER-AF cluster-randomized trial reveals that structured professional education significantly boosts adherence to complex rhythm control guidelines in atrial fibrillation, though it shows no significant impact on stroke prevention where baseline performance is already high.
Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial
Posted inCardiology Internal Medicine news

Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial

The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial
Posted inCardiology Internal Medicine news

Intensive Blood Pressure Control to <120 mmHg: Holistic Benefits Across Frailty, Quality of Life, and Microvascular Health in the ESPRIT Trial

The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microvascular health and maintaining patient quality of life.